Metabasis Therapeutics, Inc. Announces Collaboration with Roche to Develop Liver-Targeted Compounds for the Treatment of Hepatitis C

www.biospace.com | Aug 8, 2008

SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX - News) announced today that it has entered into a two-year research collaboration agreement with Roche to apply Metabasis HepDirect liver-targeting technology to Roches proprietary lead nucleosides in order to develop new

http://www.biospace.com/news_story.aspx?StoryID=106296&full=1

Metabasis extends collaboration with Merck

www.pharmaceutical-business-review.com | Apr 23, 2008

Metabasis Therapeutics has announced an extension to the sponsored research term under its collaboration with Merck & Co. for an additional year, through June 2009.

http://www.pharmaceutical-business-review.com/article_news.asp?guid=D7B19B0A-9480-4CCE-AB43-D81F3FCF666E

Metabasis Therapeutics says product gets orphan status

www.marketwatch.com | Sep 10, 2007

NEW YORK (MarketWatch) - Metabasis Therapeutics on Monday said that MB07133, its product candidate for the treatment of hepatocellular carcinoma, or primary liver cancer, has been granted orphan drug designation by the Food and Drug Administration. Primary liver cancer represents the fifth most

http://www.marketwatch.com/news/story/metabasis-therapeutics-says-product-gets/story.aspx?guid=%7B0FFBD64F%2D57F7%2D458F%2D8CDB%2DA68366D2AF17%7D&siteid=rss

Merck Adds to Its Growing Roster of Oncology Drugs-05/07/2004-CMR

www.icis.com | Jul 2, 2004

Capitalizing on technology sy-nergies captured through the acquisition of Rosetta Inpharmatics, Merck & Co.

http://www.icis.com/Articles/2004/07/02/594520/merck-adds-to-its-growing-roster-of-oncology-drugs.html

MBRX: To Present At Oppenheimer Healthcare Conference @ 08:40 ET [delayed] - Zibb.com

www.zibb.com

Company representatives of Metabasis Therapeutics Inc (NasdaqNM: MBRX) will be presenting at the Oppenheimer 19th Annual Healthcare Conference today. The Company's presentation is scheduled to begin at 08:40 ET. Expected Speaker(s): Dr. Paul Laikind, President and CEO ** Conference

http://www.zibb.com/article/4302840/MBRX+To+Present+At+Oppenheimer+Healthcare+Conference+ET+delayed

Up-To-Date Information For Hepatitis B

April 4, 2003 Metabasis Therapeutics, Inc. Announces the Commencement of Clinical Testing of Hepavir B in Patients With Hepatitis B [PR Newswire] PR via NewsEdge Corporation : SAN DIEGO, April 3 /PRNewswire/ -- Metabasis Therapeutics, Inc. (Metabasis) announced today that Ribapharm, Inc.

http://www.frontline-hepatitis-awareness.com/hepbinfo.htm

EvaluatePharma - Metabasis Therapeutics Sample Information

EvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.

http://www.evaluatepharma.com/CoInfo/CoInfo-MBRX.htm

Metabasis Therapeutics - Analyst News | newratings.com

Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.

http://www.newratings.com/headlines/Metabasis-Therapeutics_US59101M1053.html